Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melvin Spigelman

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Current Opinion in Pharmacology|August 15, 2006
Novel targets for tuberculosis drug discoveryKhisimuzi Mdluli, Melvin Spigelman
Lancet (London, England)|March 21, 2006
Tuberculosis drug development pipeline: progress and hopeMelvin Spigelman, Stephen Gillespie
Expert Review of Anti-Infective Therapy|October 16, 2004
Mycobacterium tuberculosis: new tricks for an old bugMelvin Spigelman, Zhenkun Ma
Nature Medicine|March 8, 2007
Challenges in tuberculosis drug research and developmentAnn M Ginsberg, Melvin Spigelman
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 31, 2008
Advancing the science in clinical trials for new TB drugsWilliam Burman, David McNeeley, Lawrence H Moulton, et al.
Antimicrobial Agents and Chemotherapy|August 28, 2019
Daily Dosing for Bedaquiline in Patients with TuberculosisDavid H Salinger, Jerry R Nedelman, Carl Mendel, et al.
Bulletin of the World Health Organization|May 9, 2017
Tuberculosis and antimicrobial resistance - new models of research and development neededGrania Brigden, José Luis Castro, Lucica Ditiu, et al.
Nature Reviews. Disease Primers|October 28, 2016
TuberculosisMadhukar Pai, Marcel A Behr, David Dowdy, et al.
BMJ Open|December 4, 2021
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the PhilippinesGabriela Beatriz Gomez, Mariana Siapka, Francesca Conradie, et al.
The Lancet. Infectious Diseases|October 20, 2018
Analysis of the clinical antibacterial and antituberculosis pipelineUrsula Theuretzbacher, Simon Gottwalt, Peter Beyer, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Current Opinion in Pharmacology|August 15, 2006
Novel targets for tuberculosis drug discoveryKhisimuzi Mdluli, Melvin Spigelman
Lancet (London, England)|March 21, 2006
Tuberculosis drug development pipeline: progress and hopeMelvin Spigelman, Stephen Gillespie
Expert Review of Anti-Infective Therapy|October 16, 2004
Mycobacterium tuberculosis: new tricks for an old bugMelvin Spigelman, Zhenkun Ma
Nature Medicine|March 8, 2007
Challenges in tuberculosis drug research and developmentAnn M Ginsberg, Melvin Spigelman
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 31, 2008
Advancing the science in clinical trials for new TB drugsWilliam Burman, David McNeeley, Lawrence H Moulton, et al.
Antimicrobial Agents and Chemotherapy|August 28, 2019
Daily Dosing for Bedaquiline in Patients with TuberculosisDavid H Salinger, Jerry R Nedelman, Carl Mendel, et al.
Bulletin of the World Health Organization|May 9, 2017
Tuberculosis and antimicrobial resistance - new models of research and development neededGrania Brigden, José Luis Castro, Lucica Ditiu, et al.
Nature Reviews. Disease Primers|October 28, 2016
TuberculosisMadhukar Pai, Marcel A Behr, David Dowdy, et al.
BMJ Open|December 4, 2021
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the PhilippinesGabriela Beatriz Gomez, Mariana Siapka, Francesca Conradie, et al.
The Lancet. Infectious Diseases|October 20, 2018
Analysis of the clinical antibacterial and antituberculosis pipelineUrsula Theuretzbacher, Simon Gottwalt, Peter Beyer, et al.
Pageof 3